LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis.

    Vinci, C / Infantino, M / Raturi, S / Tindell, A / Topping, L M / Strollo, R / Amital, H / Shoenfeld, Y / Gertel, S / Grossi, V / Manfredi, M / Rutigliano, I M / Bandinelli, F / Li Gobbi, F / Damiani, A / Pozzilli, P / Mcinnes, I B / Goodyear, C S / Benucci, M /
    Nissim, A

    Scandinavian journal of rheumatology

    2020  Volume 49, Issue 4, Page(s) 281–291

    Abstract: Objectives: The discovery of diseased tissue-specific neoantigens offers the opportunity to develop important disease tissue-specific biomarkers that can help in the prediction, diagnosis, and stratification of diseases. This opportunity is specifically ...

    Abstract Objectives: The discovery of diseased tissue-specific neoantigens offers the opportunity to develop important disease tissue-specific biomarkers that can help in the prediction, diagnosis, and stratification of diseases. This opportunity is specifically significant for autoimmune diseases where diagnostic biomarkers are not available. Inflammatory autoimmune diseases are commonly associated with local generation of large amounts of reactive oxidants. We have previously identified oxidative post-translationally modified (oxPTM) tissue-specific neoantigens in rheumatoid arthritis (RA) and type 1 diabetes that elicit an immune response. In the current study, we studied the presence and clinical significance of antibodies to oxPTM collagen type II (CII) in patients with spondyloarthritis (SpA).
    Method: Levels of antibodies specific to native CII and oxPTM-CII were assessed by enzyme-linked immunosorbent assay.
    Results: Immunoglobulin G (IgG) binding to oxPTM-CII was observed in 52%, 83%, and 28% of serum samples from patients with axial spondyloarthritis (axSpA), RA, and psoriatic arthritis (PsA), respectively. Importantly, while strong IgA anti-oxPTM-CII responses were detected in axSpA and PsA patients, with 47% and 84% respective binders, no IgA anti-oxPTM-CII was detected in RA patients. IgA anti-oxPTM-CII reactivity in axSpA patients treated with biologics was higher and more frequent, with 85% binders compared to 9% binders in patients treated with synthetic disease-modifying anti-rheumatic drugs.
    Conclusion: Our data imply that SpA and PsA are associated with the presence of antibodies to oxPTM-CII, suggesting that there may be a humoral component that may distinguish patients with SpA from RA. Our approach could be adapted to other diseases, particularly to inflammatory autoimmune diseases.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Arthritis, Psoriatic/blood ; Arthritis, Psoriatic/diagnosis ; Arthritis, Psoriatic/immunology ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/immunology ; Biomarkers/blood ; Case-Control Studies ; Collagen Type II/immunology ; Collagen Type II/metabolism ; Diagnosis, Differential ; Female ; Humans ; Immunoglobulin A/blood ; Immunoglobulin A/immunology ; Male ; Middle Aged ; Oxidation-Reduction ; Protein Processing, Post-Translational ; Spondylarthropathies/blood ; Spondylarthropathies/diagnosis ; Spondylarthropathies/immunology
    Chemical Substances Biomarkers ; Collagen Type II ; Immunoglobulin A
    Language English
    Publishing date 2020-04-21
    Publishing country England
    Document type Journal Article ; Multicenter Study
    ZDB-ID 121265-5
    ISSN 1502-7732 ; 0300-9742
    ISSN (online) 1502-7732
    ISSN 0300-9742
    DOI 10.1080/03009742.2020.1713395
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Recombinant human Dnase I (rhDNase) in patients with lupus nephritis.

    Davis, J C / Manzi, S / Yarboro, C / Rairie, J / Mcinnes, I / Averthelyi, D / Sinicropi, D / Hale, V G / Balow, J / Austin, H / Boumpas, D T / Klippel, J H

    Lupus

    1999  Volume 8, Issue 1, Page(s) 68–76

    Abstract: Systemic lupus erythematosus (SLE) is characterized by the production of pathogenic autoantibodies to nucleoprotein antigens, including double-stranded DNA (dsDNA). The deposition of IgG dsDNA immune complexes in glomeruli is thought to be crucial for ... ...

    Abstract Systemic lupus erythematosus (SLE) is characterized by the production of pathogenic autoantibodies to nucleoprotein antigens, including double-stranded DNA (dsDNA). The deposition of IgG dsDNA immune complexes in glomeruli is thought to be crucial for disease pathogenesis and complement activation. rhDNase catalyzes the hydrolysis of extracellular DNA and has been shown to delay the development of dsDNA antibodies, reduce proteinuria, and delay mortality in a lupus-prone murine model. We conducted a 40d, phase Ib, randomized, double-masked, placebo-controlled trial to determine the safety and pharmacokinetics of rhDNase, and to measure any changes in markers of disease activity in 17 patients with lupus nephritis. Patients were assigned to receive either: (1) 25 microg/kg rhDNase (n = 8); (2) 125 microg/kg rhDNase (n=6); or (3) placebo (n = 3) initial single intravenous (IV) dose followed by 10 subcutaneous (SC) doses. Skin biopsies performed on nine patients pre- and post-treatment were studied for immune complex deposition by immunofluorescence. Serum cytokine levels (sIL2-R, IL-6, IL-10, and TNF-alpha) were analyzed by ELISA. Cytokine secretion and antibody production were measured by ELISPOT analysis and ELISA. Serum hydrolytic activity of rhDNase was achieved after IV administration at 25 and 125 microg/kg, but not after SC administration at either dose. A t 1/2 of 3-4h was estimated from serum concentration profiles following IV administration. Serum dsDNA antibodies were unchanged (mean values: 33 IU/mL vs 39 IU/mL [pre- and post-treatment] for the 25 microg/kg group, and 74 IU/mL vs 74 IU/mL for the 125 microg/kg group, and 14 IU/mL vs 20 IU/mL for the placebo group). Complement levels (C3 and C4) and circulating immune complexes did not change appreciably during the treatment period for any of the groups. Serum cytokine profiles by ELISA revealed no changes in sIL-2 receptor, IL-6, IL-10, or TNF-alpha. There was no change in the number of cells secreting either Th1 or Th2 specific cytokines, nor in the number of cells secreting dsDNA antibodies. Neutralizing antibodies to rhDNase were not detected in serum at any time during the study. Immune complex deposition was unchanged in pre- and post-treatment in skin biopsies in both dose groups. rhDnase was well tolerated without significant adverse events following administration, and treatment was not associated with the development of neutralizing antibodies to rhDNase. Serum rhDNase concentrations capable of hydrolytic activity of rhDNase were achieved for a few hours following IV, but not SC administration. Serum markers of disease activity were unchanged during the study period.
    MeSH term(s) Adult ; Deoxyribonuclease I/adverse effects ; Deoxyribonuclease I/pharmacokinetics ; Deoxyribonuclease I/therapeutic use ; Double-Blind Method ; Female ; Humans ; Lupus Nephritis/drug therapy ; Male ; Recombinant Proteins/therapeutic use
    Chemical Substances Recombinant Proteins ; Deoxyribonuclease I (EC 3.1.21.1)
    Language English
    Publishing date 1999
    Publishing country England
    Document type Clinical Trial ; Clinical Trial, Phase I ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 1154407-7
    ISSN 0961-2033
    ISSN 0961-2033
    DOI 10.1191/096120399678847380
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: IDIOPATHIC HAEMOCHROMATOSIS IN CHILDREN; REPORT OF A FAMILY.

    PERKINS, K W / MCINNES, I W / BLACKBURN, C R / BEAL, R W

    The American journal of medicine

    1965  Volume 39, Page(s) 118–126

    MeSH term(s) Adolescent ; Blood ; Blood Group Antigens ; Bloodletting ; Child ; Genetics, Medical ; Hemochromatosis ; Hemoglobins ; Humans ; Iron ; Pathology
    Chemical Substances Blood Group Antigens ; Hemoglobins ; Iron (E1UOL152H7)
    Language English
    Publishing date 1965-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/0002-9343(65)90251-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top